Renal Impairment Is Frequent in Chronic Hepatitis C Patients Under Triple Therapy With Telaprevir or Boceprevir Reply

被引：0
|
作者：
Gordon, Stuart C. [1 ]
Yee, Leland J. [2 ]
Martins, Eduardo Bruno [2 ]
机构：
[1] Henry Ford Hosp, Detroit, MI 48202 USA
[2] Gilead Sci, Foster City, CA USA
来源：
HEPATOLOGY | 2014年 / 59卷 / 06期
关键词：
D O I：
10.1002/hep.26902
中图分类号：
R57 [消化系及腹部疾病];
学科分类号：
摘要：
引用
收藏
页码：2427 / 2427
页数：1
相关论文
共 50 条
  • [31] Triple Therapy for Hepatitis C Infection in the Real World: Practice Trends Following the Release of Boceprevir and Telaprevir
    Chen, Emerson Y.
    Sclair, Seth N.
    Czul, Frank
    Apica, Betty S.
    Martin, Paul
    Lee, William M.
    HEPATOLOGY, 2012, 56 : 259A - 259A
  • [32] Triple combination therapy for hepatitis C with telaprevir exhibits greater early antiviral activity than with boceprevir
    Benito, Jose M.
    Sanchez-Parra, Clara
    Maida, Ivana
    Aguilera, Antonio
    Rallon, Norma I.
    Rick, Fernanda
    Labarga, Pablo
    Fernandez-Montero, Jose V.
    Barreiro, Pablo
    Soriano, Vincent
    ANTIVIRAL THERAPY, 2013, 18 (05) : 709 - 715
  • [33] The Real Life Effectiveness of Telaprevir Triple Therapy in Chronic Hepatitis C
    Al-Bawardy, Badr
    Kim, W. Ray
    Poterucha, John
    Charlton, Michael
    Canterbury, Katherine
    Gross, John
    AMERICAN JOURNAL OF GASTROENTEROLOGY, 2012, 107 : S170 - S170
  • [34] Severe renal impairment during triple therapy with telaprevir
    Carrier, P.
    Chambaraud, T.
    Vong, C.
    Guillaudeau, A.
    Debette-Gratien, M.
    Jacques, J.
    Legros, R.
    Sautereaua, D.
    Essig, M.
    Loustaud-Ratti, V.
    CLINICS AND RESEARCH IN HEPATOLOGY AND GASTROENTEROLOGY, 2014, 38 (04) : E69 - E71
  • [35] Cost-effectiveness of boceprevir or telaprevir for untreated patients with genotype 1 chronic hepatitis C
    Camma, Calogero
    Petta, Salvatore
    Enea, Marco
    Bruno, Raffaele
    Bronte, Fabrizio
    Capursi, Vincenza
    Cicchetti, Americo
    Colombo, Giorgio L.
    Di Marco, Vito
    Gasbarrini, Antonio
    Craxi, Antonio
    HEPATOLOGY, 2012, 56 (03) : 850 - 860
  • [36] Letter: telaprevir triple therapy in chronic hepatitis C genotype 1 patients receiving haemodialysis
    Wiegand, J.
    Maasoumy, B.
    Buggisch, P.
    Buslau, A.
    Schiefke, I.
    Berg, T.
    Wedemeyer, H.
    Sarrazin, C.
    Hinrichsen, H.
    ALIMENTARY PHARMACOLOGY & THERAPEUTICS, 2014, 39 (11) : 1342 - 1344
  • [37] Evaluation of telaprevir-containing triple therapy in the treatment of chronic hepatitis C in hemodialysed patients
    Kaya, Safak
    Aksoz, Selcuk
    Baysal, Birol
    Ay, Nurettin
    Danis, Ramazan
    INFECTIOUS DISEASES, 2015, 47 (09) : 658 - 661
  • [38] The Effect of Telaprevir-Based Triple Therapy for Chronic Hepatitis C Patients on Gastric Emptying
    Arai, Makoto
    Oyamada, Arata
    Maruoka, Daisuke
    Matsumura, Tomoaki
    Nakagawa, Tomoo
    Kanda, Tastuo
    Katsuno, Tatsuro
    Imazeki, Fumio
    Yokosuka, Osamu
    GASTROENTEROLOGY, 2014, 146 (05) : S615 - S616
  • [39] Telaprevir and Boceprevir in African Americans with Genotype 1 Chronic Hepatitis C: Implications for Patients and Providers
    Burton, Mary Jane
    Passarella, Michael J.
    McGuire, Brendan M.
    SOUTHERN MEDICAL JOURNAL, 2012, 105 (08) : 431 - 436
  • [40] The safety and tolerability of telaprevir and boceprevir based triple therapy for hepatitis C genotype 1 in an Irish patient cohort
    El-Sherif, O.
    Quinn, C.
    Hynes, B.
    McGrath, M.
    Irish, H.
    McKiernan, S.
    Norris, S.
    IRISH JOURNAL OF MEDICAL SCIENCE, 2015, 184 : S54 - S55
12345